Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. De Vore, P. M. De Porre, H. M. Richards, X. Jia, S. Zhang, B. E. Johnson

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: R115777 (tipifarnib, Zarnestra ™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival. This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC). Patients and methods: Patients who had a partial or complete response to their initial chemotherapy regimen, followed by at least 3 months off treatment before relapse (sensitive relapse) were eligible. R115777 was administered in 3-week cycles at a dose of 400mg orally twice daily for 14 consecutive days followed by 7 days off treatment. Results: Twenty-two patients were enrolled. The median progression-free survival was 1.4 months and median overall survival was 6.8 months. Non-hematological toxicities were predominantly grade 1-2 and included nausea (64%) and fatigue (60%). Grade 3-4 granulocytopenia and thrombocytopenia occurred in 27% and 23% of patients, respectively. Febrile neutropenia was not observed. Pharmacokinetic studies demonstrated peak plasma concentrations of R115777 2.6-4.5h after oral dosing and no significant drug accumulation. The trial was terminated because no objective responses were observed in 20 patients evaluable for response. Conclusions: R115777 showed no significant antitumor activity as a single agent in sensitive-relapse SCLC.

Original languageEnglish (US)
Pages (from-to)1187-1193
Number of pages7
JournalAnnals of Oncology
Volume15
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

tipifarnib
Small Cell Lung Carcinoma
Transferases
Recurrence
Pharmacokinetics
Protein Prenylation
Febrile Neutropenia
Agranulocytosis
Nausea
Disease-Free Survival
Fatigue
Signal Transduction
Cell Survival
Cell Proliferation
Drug Therapy

Keywords

  • Farnesyl transferase inhibitor
  • R115777
  • Ras
  • Small-cell lung cancer
  • Tipifarnib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. / Heymach, J. V.; Johnson, D. H.; Khuri, F. R.; Safran, H.; Schlabach, L. L.; Yunus, F.; De Vore, R. F.; De Porre, P. M.; Richards, H. M.; Jia, X.; Zhang, S.; Johnson, B. E.

In: Annals of Oncology, Vol. 15, No. 8, 08.2004, p. 1187-1193.

Research output: Contribution to journalArticle

Heymach, JV, Johnson, DH, Khuri, FR, Safran, H, Schlabach, LL, Yunus, F, De Vore, RF, De Porre, PM, Richards, HM, Jia, X, Zhang, S & Johnson, BE 2004, 'Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer', Annals of Oncology, vol. 15, no. 8, pp. 1187-1193. https://doi.org/10.1093/annonc/mdh315
Heymach, J. V. ; Johnson, D. H. ; Khuri, F. R. ; Safran, H. ; Schlabach, L. L. ; Yunus, F. ; De Vore, R. F. ; De Porre, P. M. ; Richards, H. M. ; Jia, X. ; Zhang, S. ; Johnson, B. E. / Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. In: Annals of Oncology. 2004 ; Vol. 15, No. 8. pp. 1187-1193.
@article{145bec70a11b4c53b6745e9e48e76b13,
title = "Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer",
abstract = "Background: R115777 (tipifarnib, Zarnestra ™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival. This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC). Patients and methods: Patients who had a partial or complete response to their initial chemotherapy regimen, followed by at least 3 months off treatment before relapse (sensitive relapse) were eligible. R115777 was administered in 3-week cycles at a dose of 400mg orally twice daily for 14 consecutive days followed by 7 days off treatment. Results: Twenty-two patients were enrolled. The median progression-free survival was 1.4 months and median overall survival was 6.8 months. Non-hematological toxicities were predominantly grade 1-2 and included nausea (64{\%}) and fatigue (60{\%}). Grade 3-4 granulocytopenia and thrombocytopenia occurred in 27{\%} and 23{\%} of patients, respectively. Febrile neutropenia was not observed. Pharmacokinetic studies demonstrated peak plasma concentrations of R115777 2.6-4.5h after oral dosing and no significant drug accumulation. The trial was terminated because no objective responses were observed in 20 patients evaluable for response. Conclusions: R115777 showed no significant antitumor activity as a single agent in sensitive-relapse SCLC.",
keywords = "Farnesyl transferase inhibitor, R115777, Ras, Small-cell lung cancer, Tipifarnib",
author = "Heymach, {J. V.} and Johnson, {D. H.} and Khuri, {F. R.} and H. Safran and Schlabach, {L. L.} and F. Yunus and {De Vore}, {R. F.} and {De Porre}, {P. M.} and Richards, {H. M.} and X. Jia and S. Zhang and Johnson, {B. E.}",
year = "2004",
month = "8",
doi = "10.1093/annonc/mdh315",
language = "English (US)",
volume = "15",
pages = "1187--1193",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

AU - Heymach, J. V.

AU - Johnson, D. H.

AU - Khuri, F. R.

AU - Safran, H.

AU - Schlabach, L. L.

AU - Yunus, F.

AU - De Vore, R. F.

AU - De Porre, P. M.

AU - Richards, H. M.

AU - Jia, X.

AU - Zhang, S.

AU - Johnson, B. E.

PY - 2004/8

Y1 - 2004/8

N2 - Background: R115777 (tipifarnib, Zarnestra ™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival. This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC). Patients and methods: Patients who had a partial or complete response to their initial chemotherapy regimen, followed by at least 3 months off treatment before relapse (sensitive relapse) were eligible. R115777 was administered in 3-week cycles at a dose of 400mg orally twice daily for 14 consecutive days followed by 7 days off treatment. Results: Twenty-two patients were enrolled. The median progression-free survival was 1.4 months and median overall survival was 6.8 months. Non-hematological toxicities were predominantly grade 1-2 and included nausea (64%) and fatigue (60%). Grade 3-4 granulocytopenia and thrombocytopenia occurred in 27% and 23% of patients, respectively. Febrile neutropenia was not observed. Pharmacokinetic studies demonstrated peak plasma concentrations of R115777 2.6-4.5h after oral dosing and no significant drug accumulation. The trial was terminated because no objective responses were observed in 20 patients evaluable for response. Conclusions: R115777 showed no significant antitumor activity as a single agent in sensitive-relapse SCLC.

AB - Background: R115777 (tipifarnib, Zarnestra ™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival. This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC). Patients and methods: Patients who had a partial or complete response to their initial chemotherapy regimen, followed by at least 3 months off treatment before relapse (sensitive relapse) were eligible. R115777 was administered in 3-week cycles at a dose of 400mg orally twice daily for 14 consecutive days followed by 7 days off treatment. Results: Twenty-two patients were enrolled. The median progression-free survival was 1.4 months and median overall survival was 6.8 months. Non-hematological toxicities were predominantly grade 1-2 and included nausea (64%) and fatigue (60%). Grade 3-4 granulocytopenia and thrombocytopenia occurred in 27% and 23% of patients, respectively. Febrile neutropenia was not observed. Pharmacokinetic studies demonstrated peak plasma concentrations of R115777 2.6-4.5h after oral dosing and no significant drug accumulation. The trial was terminated because no objective responses were observed in 20 patients evaluable for response. Conclusions: R115777 showed no significant antitumor activity as a single agent in sensitive-relapse SCLC.

KW - Farnesyl transferase inhibitor

KW - R115777

KW - Ras

KW - Small-cell lung cancer

KW - Tipifarnib

UR - http://www.scopus.com/inward/record.url?scp=4444236880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444236880&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh315

DO - 10.1093/annonc/mdh315

M3 - Article

C2 - 15277257

AN - SCOPUS:4444236880

VL - 15

SP - 1187

EP - 1193

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -